The Week in Review: April 28, 2017 – May 5, 2017

Friday, May 5, 2017 News Recap Canada Great news from Nova Scotia: Expanded access to and coverage for treatment of chronic hepatitis C is now available under the provincial Pharmacare plan, similar to the new arrangements in BC, Alberta, Ontario, Saskatchewan and Quebec.  The drugs covered are: Epclusa, Daklinza, Sunvepra, Zepatier, Harvoni and Sovaldi. You can read the Nova Scotia Pharmacare Formulary Updates here (Nova Scotia Lists EPCLUSA™ on P...

I-MAK Wins: Gilead Loses Appeal on Sofosbuvir Patent in China

The China patent office’s re-examination board has upheld June 2015 rejection of a critical sofosbuvir patent, denying Gilead’s appeal on I-MAK’s winning case. The patent office ruled that the sofosbuvir prodrug did not deserve a patent under the law. This comes as I-MAK just filed a new legal challenge against the sofosbuvir base compound in China  on April 19th, 2017. Freeing sofosbuvir of its unmerited patents in the country would open the door to affo

Hepatitis C Patent Challenges In India, Argentina To Allow Generic Production

Resistance to high prices for hepatitis C drugs is ongoing as five new challenges against patents have been filed in India and Argentina, according to sources. Those challenges aim at allowing the production and distribution of affordable generic versions of new hepatitis C medicines (direct-acting antivirals). According to a Médecins Sans Frontières (MSF, Doctors Without Borders) press release, on 13 February the Initiative for Medicines, Access & Kn

All You Need to Know: September’s Crucial Verdict on the Sofosbuvir Patent Saga

The patent also covers the raw materials to make the drugs, which means it would allow the manufacturer to disrupt exports of the raw materials from India. In September, India will witness the first hearing in a crucial court case on the grant of a patent for the anti-hepatitis-C drug sofosbuvir – a drug whose patent was rejected and then approved by the same patent court, albeit by two different officials. A recent report of the international medical cha

Gilead gets patent for Hepatitis C drug Sovaldi

The decision is a major blow to the access to drug movement, says MSF In direct contradiction to its earlier order, the Controller General of Patents, Designs and Trademark granted American pharmaceutical company Gilead Sciences the patent for the blockbuster Hepatitis C drug Sofosbuvir (brand name Sovaldi) in India. An application for the same patent was first rejected in January 2015 as lacking inventiveness and novelty. On Monday, however, the pa...